Skip to content
No results
  • About MAPRx
    • Our Members
  • Part D Information and Resources
  • 2026 Priorities
  • MAPRx In Action
MAPRx.info
  • About MAPRx
    • Our Members
  • Part D Information and Resources
  • 2026 Priorities
  • MAPRx In Action
MAPRx.info
  • Policy Position and Comment Letters

MAPRx Submits Comments to CMS on Medicare Prescription Payment Plan

Earlier today the MAPRx Coalition submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the memorandum Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for…

  • MAPRx
  • March 15, 2024
  • Policy Position and Comment Letters

MAPRx Releases Issue Brief: Part D Benefit Redesign

Earlier today the MAPRx Coalition released the Issue Brief: Minimizing Affordability Challenges and Beneficiary Confusion. Linked HERE. Highlights of the Issue Brief: Key finalized provisions from Part 1 Guidance Key proposed provisions from Part 2 Guidance Key insights from coalition…

  • MAPRx
  • March 15, 2024
  • Policy Position and Comment Letters

MAPRx Submits Comments to CMS on Monthly Payment Cap Implementation

Earlier today, the MAPRx Coalition submitted comments to the Centers for Medicare & Medicaid Services (CMS) regarding the implementation of the Medicare Prescription Payment Plan program set to take effect for Contract Year (CY) 2025 per the Memorandum Maximum Monthly…

  • MAPRx
  • September 20, 2023
  • Policy Position and Comment Letters

MAPRx Submits Comments to CMS on Medicare Drug Price Negotiation Program

Earlier today, the MAPRx Coalition submitted to the Centers for Medicare & Medicaid Services (CMS) comments regarding the implementation of the Medicare Drug Price Negotiation Program (MDPNP) for initial price applicability year 2026. The Coalition appreciates the opportunity to comment…

  • MAPRx
  • April 24, 2023
  • Policy Position and Comment Letters

New MAPRx Report Examines the Exclusion of Anti-Obesity Medications in Medicare Part D

A new report commissioned by the MAPRx Coalition examines the growing clinical evidence for coverage of anti-obesity medications (AOMs) approved by the Food and Drug Administration in Medicare Part D. As the medical community’s understanding of disease states evolves, MAPRx…

  • MAPRx
  • September 14, 2022
  • Policy Position and Comment Letters

MAPRx Submits Letter to Senate Leaders on Inflation Reduction Act

Earlier today, the MAPRx Coalition and 35 member organizations submitted a letter to Senate leadership ahead of their continued consideration of the Inflation Reduction Act of 2022 via the Senate’s reconciliation process. While members of the Coalition have differing views…

  • MAPRx
  • August 4, 2022
  • Policy Position and Comment Letters

MAPRx Letter to Congressional Leaders Supports Out-of-Pocket Cap

Earlier today, 29 members of the MAPRx Coalition sent a letter to Congressional leaders urging them to establish an out-of-pocket (OOP) cap for Medicare Part D to limit the amount Medicare beneficiaries have to pay for covered prescription drugs. The…

  • MAPRx
  • September 9, 2021
  • News

MAPRx Hosts Capitol Hill Briefing Urging Beneficiary Out-of-Pocket Cap

Earlier today, the MAPRx Coalition hosted a virtual briefing for members of Congress, their staff, and MAPRx member organizations. After Corey Ford of Xcenda provided an overview of the Medicare Part D benefit, Illy Jaffer of the American Cancer Society…

  • MAPRx
  • July 22, 2021
Prev1 2 3 4 5 6Next
No more posts to load

☷Filters

By Topic
By Type
  • X

About MAPRx

  • About Us
  • Our Members

Resources

  • 2026 Priorities
  • Part D Information and Resources
  • MAPRx in Action

© 2026 - MAPRx Medicare Access for Patients RX™. All rights reserved.

Bonnie@maprxinfo.org